RU 59063: a non-steroidal antiandrogen; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 197655 |
| CHEMBL ID | 331820 |
| SCHEMBL ID | 1714908 |
| MeSH ID | M0229216 |
| Synonym |
|---|
| ru 59063 |
| 4-(3-(4-hydroxybutyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile |
| bdbm50091400 |
| 4-[3-(4-hydroxy-butyl)-4,4-dimethyl-5-oxo-2-thioxo-imidazolidin-1-yl]-2-trifluoromethyl-benzonitrile |
| ru-59063 |
| CHEMBL331820 , |
| 4-[3-(4-hydroxybutyl)-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile |
| ru59063 |
| 4-(4,4-dimethyl-3-(4-hydroxybutyl)-5-oxo-2-thioxo-1-imidazolidinyl)-2-(trifluoromethyl)benzonitrile |
| 3lrs7fxn3g , |
| unii-3lrs7fxn3g |
| benzonitrile, 4-(3-(4-hydroxybutyl)-4,4-dimethyl-5-oxo-2-thioxo-1-imidazolidinyl)-2-(trifluoromethyl)- |
| 155180-53-3 |
| 4-[3-(4-hydroxybutyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile |
| SY008557 |
| mfcd00925775 |
| AKOS016845838 |
| 4-(4,4-dimethyl 3-(4-hydroxybutyl)-5-oxo 2-thioxo-1-imidazolidinyl) 2-(trifluoromethyl) benzonitrile |
| 4-(4,4-dimethyl 3-(4-hydroxybutyl)-5-oxo 2-thioxo-1-imidazolidinyl) 2-(trifluoromethyl) benzonitile |
| SCHEMBL1714908 |
| c17h18f3n3o2s |
| DTXSID50165850 |
| FT-0739125 |
| DS-4755 |
| AMY20328 |
| benzonitrile, 4-[3-(4-hydroxybutyl)-4,4-dimethyl-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- |
| 4-(4,4-dimethyl-3-(4-oxidanylbutyl)-5-oxidanylidene-2-sulfanylidene-imidazolidin-1-yl)-2-(trifluoromethyl)benzenecarbonitrile |
| 4-[3-(4-hydroxybutyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-trifluoromethylbenzonitrile |
| 4-[3-(4-hydroxybutyl)-4,4-dimethyl-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)benzonitrile |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Androgen receptor | Rattus norvegicus (Norway rat) | Ki | 0.0022 | 0.0003 | 1.2185 | 8.9270 | AID239949 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID482784 | Inhibition of prostate specific antigen expression in human LNCAP cells at 0.625 to 20 uM in presence of fetal bovine serum | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7 | Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). |
| AID238931 | Inhibition of rat prostate cytosolic androgen receptor | 2004 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21 | Synthesis and structure-activity investigation of iodinated arylhydantoins and arylthiohydantoins for development as androgen receptor radioligands. |
| AID482787 | Inhibition of prostate specific antigen expression in human LNCAP cells at 1.25 to 10 uM in presence of fetal bovine serum | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7 | Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). |
| AID239949 | Inhibition of [3H]mibolerone binding to cytosolic androgen receptor of rat ventral prostate | 2005 | Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4 | Three-dimensional structure-activity relationships of nonsteroidal ligands in complex with androgen receptor ligand-binding domain. |
| AID39296 | Inhibitory constant against rat prostate cytosol androgen receptor using [3H]mibolerone | 2000 | Journal of medicinal chemistry, Aug-24, Volume: 43, Issue:17 | Design, synthesis, and pharmacological characterization of 4-[4, 4-dimethyl-3-(4-hydroxybutyl)-5-oxo-2-thioxo-1-imidazolidinyl]- 2-iodobenzonitrile as a high-affinity nonsteroidal androgen receptor ligand. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||